Al Sandrock (Biogen via YouTube)
July 27, 2021 07:42 AM EDTUpdated 07:53 AM
R&D

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

Amber Tong

Even as Bio­gen ex­ecs scram­bled to de­fend Aduhelm and paint a rosy fu­ture the drug promis­es to un­leash, R&D chief Al San­drock re­as­sured an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times